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Abstract
The antiepileptic drug Levetiracetam (Lev) has neuroprotective properties in experimental stroke, cerebral
hemorrhage and neurotrauma. In these conditions, non-convulsive seizures (NCSs) propagate from the core of the
focal lesion into perilesional tissue, enlarging the damaged area and promoting epileptogenesis. Here, we explore
whether Lev neuroprotective effect is accompanied by changes in NCS generation or propagation. In particular, we
performed continuous EEG recordings before and after the permanent occlusion of the middle cerebral artery
(pMCAO) in rats that received Lev (100 mg/kg) or its vehicle immediately before surgery. Both in Lev-treated and in
control rats, EEG activity was suppressed after pMCAO. In control but not in Lev-treated rats, EEG activity
reappeared approximately 30-45 min after pMCAO. It initially consisted in single spikes and, then, evolved into spike-
and-wave and polyspike-and-wave discharges. In Lev-treated rats, only rare spike events were observed and the
EEG power was significantly smaller than in controls. Approximately 24 hours after pMCAO, EEG activity increased
in Lev-treated rats because of the appearance of polyspike events whose power was, however, significantly smaller
than in controls. In rats sacrificed 24 hours after pMCAO, the ischemic lesion was approximately 50% smaller in Lev-
treated than in control rats. A similar neuroprotection was observed in rats sacrificed 72 hours after pMCAO. In
conclusion, in rats subjected to pMCAO, a single Lev injection suppresses NCS occurrence for at least 24 hours.
This electrophysiological effect could explain the long lasting reduction of ischemic brain damage caused by this
drug.
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Introduction
Levetiracetam (Lev) is a second generation antiepileptic drug
structurally related to the nootropic and neuroprotective
pyrrolidone compound, piracetam [1]. Beside its potent
antiepileptic activity, Lev also has antiepileptogenic effects in
electrical [2,3] and audiogenic kindling [4] and in several animal
models of epilepsy such as WAG/Rij rats [5,6]. In addition, this
drug protects neurons from different types of insults including
the intracerebroventricular injection of kainate [7] and brain
ischemia induced by middle cerebral artery occlusion (MCAO)
[8] or neonatal hypoxia [9]. Lev also reduced brain damage in
experimental subarachnoid hemorrhage and closed head
trauma [10].
The mechanism responsible for Lev-induced neuroprotection
and antiepileptogenic effect is unknown. This drug differs from
all known antiepileptics for it targets SV2, a protein of the
synaptic vesicle fusion complex [11]. Through the interaction
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with this protein, Lev acts as a general inhibitor of
neurotransmitter release [12]. Moreover, we reported that Lev
blocks Ca2+ release from intracellular IP3 stores [13] and a
similar effect was observed by others for ryanodine stores
[14,15]. Lev also antagonizes the inhibitory effect of Zn2+ and β-
carbolines on GABAA receptors [16] and has slight inhibitory
effects on N-type Ca2+ channels [17]. Finally, its major
metabolite in humans, 2-pyrrolidinone-n-butyric acid, inhibits
hystone deacetylases [18]. All these pharmacological effects
could, theoretically, contribute to neuroprotection by a direct
effect on neurons [19]. Despite its efficacy in living animals,
surprisingly, Lev was ineffective in models in vitro of
neurodegeneration. Specifically, this drug was unable to
protect hippocampal slices from the ischemic damage induced
by the combined deprivation of oxygen and glucose [20]. This
finding suggests that intact neuronal networks present in the
living brain and disrupted by the slicing procedure are
necessary for Lev-induced neuroprotection. This hypothesis is
in keeping with the evidence that after a focal brain insult,
depolarizing waves of spreading depolarization, called post-
ischemic depolarizations (PIDs), enlarge the primary lesion by
propagating into the surrounding intact brain through
preexisting synaptic networks (see 21 for review). At the EEG,
PIDs have the electrophysiological features of seizure activity.
Because they are not accompanied either by motor or
behavioral symptoms, these events are usually defined non-
convulsive seizures (NCSs) [22]. Recently, the propagation of
NCSs has been directly visualized in the ischemic human brain
and the demonstration of their relevance in the progression of
ischemic lesions has also been obtained [23]. NCSs also
contribute to epileptogenesis accounting for the frequent
development of post-ischemic epilepsy in patients surviving
stroke [24]. Therefore, a neuroprotective activity in stroke and a
protection from the development of postischemic epilepsy
could be obtained by suppressing PIDs. In the present paper,
we explored whether this electrophysiological effect could be
obtained with Lev. To this aim, we examined Lev effect on the
generation or propagation of NCSs occurring in rats after the
permanent occlusion of the middle cerebral artery (pMCAO), a
well known experimental model of brain ischemia.
Materials and Methods
Animals
All the experiments were performed in 2-month old, male,
Sprague Dawley rats weighing 200-250 g (Charles River, Italy).
Rats were group caged on a 12 h light/dark cycle and had free
access to food and water. The experimental protocol was
approved by the Animal Care Committee of “Federico II”,
University of Naples, Italy. Animal housing and experimental
procedures were performed according to the recommendations
of the guidelines for care and use of experimental animals of
The European Community Council directive (86/609/EEC). All
efforts were made to minimize animal suffering and to reduce
the number of animals used in the experiments.
Electrode Implantation
Two/three days before experimental brain ischemia or sham
operation, rats were deeply anesthetized by delivering a gas
mixture containing 2% sevoflurane in a 70% nitrous oxide/30%
oxygen through a nose cone. Then, two burr holes were drilled
in each side of the skull, 2 mm laterally to the midline, and 2
and 4 mm posteriorly to bregma to position the EEG recording
electrodes onto the dural surface. According to the Paxinos
and Watson coordinates, these positions correspond to the
parietal region of the neocortex. In addition, a reference
electrode was placed posterior to lambda. The electrodes were
secured to the skull with acrylic dental cement. Their free ends
were soldered to a multipin connector (Plastic One, Roanoke,
VA, USA) and the entire assembly was fixed to the skull with
dental cement.
Basal EEG recordings
For EEG recordings, we used a bipolar recording montage
with a ground electrode placed onto the nasal bone. On the
day of the experiment, animals were placed in a recording cage
equipped with a multichannel swivel commutator (Plastics One,
Roanoke, VA, USA). The multipin connector on the rat skull
was connected to the swivel system via a flexible shielded
cable that allowed free movement of the animal during the EEG
recording [25]. The swivel commutator was interfaced through
shielded cables with an EEG recording and analysis system
(Belight, Galileo NT, EB-Neuro, Florence, Italy). Signals were
low-pass filtered at 0.1 Hz before being band-passed between
0.16 and 50 Hz. Data were digitized at 100 Hz, acquired
through the analysis software and stored on the hard disk of
the computer for offline analysis.
Basal EEG activity was recorded for 30 minutes, then, the
swivel cable was disconnected from the multipin connector on
the head of the animal. Lev or vehicle was injected as
described in the following section and the rat was deeply
anesthetized to be subjected to pMCAO as described below.
After the surgical procedure, the animal was returned to its
cage and was reconnected to the swivel cable. Twenty minutes
after the induction of ischemia, EEG recording was started
again and continued for 48 hours.
Levetiracetam administration
Lev was dissolved in saline solution and administered at the
doses of 50 or 100mg/Kg by a single intraperitoneal (ip)
injection. Drug injection and the further experimental
procedures were carried out in blind manner. Indeed, the
researchers who performed the experiments and analyzed data
were not aware of the drug treatment administered to the
animal.
Experimental brain ischemia
pMCAO was performed using the method described by
Cuomo et al. with slight modifications [26]. Briefly, rats were
deeply anesthetized with a gas mixture (4% sevoflurane in a
70% nitrous oxide/30% oxygen) delivered through a nose cone.
Anaesthesia was then maintained with 2% sevoflurane during
the entire surgical procedure. The skin of the neck and the
Levetiracetam Effect on Post-Ischemic Seizures
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underneath fasciae were sectioned in the sternocleidomastoid
region and the neurovascular bundle of the neck was exposed.
In sham-operated rats, the surgical section was, then, sutured
without proceeding further with arterial occlusion whereas in
rats undergoing pMCAO the right carotid bifurcation was
exposed and the external carotid artery coagulated distal to the
bifurcation and cut. Afterwards, a 6-0 nylon filament was
inserted through the external carotid artery stump and
advanced into the left internal carotid artery until it blocked the
origin of the middle cerebral artery. During this surgical
procedure, cortical cerebral blood flow (CBF) was continuously
monitored with a laser-doppler flowmeter (Periflux system
5000, Perimed, Milan Italy) [27]. Once a stable drop in blood
flow signal was obtained ipsilaterally to the occlusion, the
filament was secured to the vessel by ligation. The filament
was left in place to permanently occlude the middle cerebral
artery. Body temperature was monitored throughout the entire
duration of the surgical procedure and maintained at 37.5 °C
with a thermostatic blanket. Arterial blood gases were
measured before and after ischemia through a catheter
inserted into the femoral artery (Rapid lab 860; Chiron
Diagnostic, Emeryville, California, USA). Only the animals
showing a reduction in CBF of at least 70% were considered
ischemic and entered the further steps of the experimental
protocol. No significant difference in CBF was found at the
retrospective analysis of the laser-doppler flowmeter data
between among the different experimental groups (data not
shown).
Evaluation of neurological deficits and of the ischemic
volume
Neurological deficits were evaluated 24 or 72 hours after
pMCAO according to Clark’s scale [28]. The statistical
significance of the difference in the scores obtained in the
different groups of animals was assessed by non-parametric
analysis using the Nemenyi test. The threshold for statistical
significance was set at p<0.05.
The extension of the ischemic lesion was assessed 24 or 72
hours after pMCAO as described elsewhere [29]. Briefly, rats
were sacrificed by decapitation. Brains were quickly removed,
placed in ice-cold saline solution for 5 minutes and then cut into
500 µM coronal slices with a vibratome (Campden Instrument,
752M; UK). Sections were incubated for 20 minutes in a saline
solution containing 2% Triphenyl tetrazolium chloride (TTC)
and, then, fixed in 10% formalin overnight. The infarcted region
in each slice was identified as the white area after TTC
staining. The surface areas of the entire slice and of the
ischemic lesion were measured using the image analysis
software Image-Pro Plus 4.1 (Media Cybernetic, Rockville, MD,
USA) in all the slices between +4.7 and -4.9mm from bregma
according to the Paxinos atlas. These coordinates define the
brain region that usually includes the entire ischemic lesion
caused by pMCAO. The values obtained were used to
calculate the volumes of the hemisphere and of the infarcted
area in this specific region. The volume of the ischemic area
was, then, expressed, as percentage of the entire volume of
the infarcted hemisphere. By this approach, the data were
corrected for brain edema. The statistical significance of the
difference between the experimental groups was evaluated by
one-way ANOVA followed by the Newman-Keuls post hoc test.
A p value <0.05 was considered statistically significant.
EEG analysis
Qualitative EEG analysis was performed off-line by visual
examination. By using this approach, we distinguished periods
of normal activity, of reduced electrical activity, in which the
traces became close to the isoelectric, and NCS events. All the
rhythmic discharges with spike components that persisted >10
sec were classified as NCS [22,25]. NCSs were further
subdivided according to their shape into single spikes, spike-
wave, poly-spike or polyspike-waves discharges. The number,
frequency and amplitude of all these events were computed in
each of the experimental groups.
Quantitative EEG analysis was performed using the Fast
Fourier Transform (FFT) and a commercial software (Belight,
Galileo NT;EB-Neuro, Florence, Italy software). Specifically,
the bipolar signal from each neocortical area in both brain
hemispheres was processed using Fast Fourier Transform and
its main spectral components were separated. Specifically, four
main band components were identified in the frequency range
between 0.25 and 32 Hz: delta (0.25–3.9 Hz), theta (4.0–7.9
Hz), alpha (8.0–12.9 Hz) and beta (13.0–30 Hz). Both in control
and in Lev-treated rats, the mean power (in μV2) of each of
these components was computed by integration of the power
spectra in the respective frequency ranges.
All the EEG data are presented as mean±SEM. Statistical
analysis of the results of qualitative and quantitative EEG
analysis was performed by one way ANOVA, followed by the
post-hoc Tukey-Kramer test for multiple comparisons. The
threshold for significance was set at p<0.05. Computational
analysis and signal processing were performed using the
GraphPad Prism 5.0 software (GraphPad Inc., La Jolla, CA,
USA).
Drugs and chemicals
Lev was kindly provided by Dr. B. Ferrò (UCB, Italia).
Sevoflurane was from Abbott (Abbott Park, Illinois, USA)
whereas oxygen and nitrous oxide were from Air Liquide Italia
(Rome, Italy). All chemicals were of analytical grade and were
purchased from Sigma Aldrich Italia (Gallarate, Milan, Italy).
Results
Effect of Levetiracetam on ischemic brain damage in
rats subjected to pMCAO
We evaluated the effect of two different Lev concentrations,
50mg/kg and 100mg/kg on the development of ischemic brain
damage and on the appearance of neurological symptoms after
pMCAO. A first group of Lev-treated and control animals were
sacrificed 24 hours after pMCAO to assess the severity of the
ischemic lesion caused by vessel occlusion. In control rats, we
observed a large brain infarction that involved the majority of
the temporo-parietal cortex in the brain hemisphere ipsilateral
to pMCAO. This lesion extended from the cortex through the
hemispheric white matter till the striatum. In the region between
Levetiracetam Effect on Post-Ischemic Seizures
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+4.7 and -4.9mm from bregma, about 40% of the brain
hemisphere was infarcted (Figure 1A). The normalized volume
of the ischemic brain was similar to that of controls in rats
receiving 50mg/Kg Lev and significantly smaller in those
injected with 100mg/kg Lev (39.5 ± 3.1, 45.7 ± 4.2 and 21.3 ±
6.3 % of the whole hemisphere in controls and in rats receiving
50 or 100 mg/kg Lev, respectively, n=6 for each group, p<0.05
100mg/Kg vs 50mg/kg Lev and vs controls) (Figure 1A).
Relevant neurological symptoms appeared in control animals
after brain ischemia, including abnormal posture and reduced
spontaneous locomotor activity. These clinical manifestations
were markedly attenuated in rats treated with 100 mg/kg Lev
but not in those receiving the lower dose of 50mg/kg.
Accordingly, Clark’s score was significantly lower in rats
receiving 100mg/kg Lev respect to the other two groups of
animals (median of deficit scores: 3.5 for vehicle treated rats vs
3 for 100mg/kg Lev treated rats, p<0.05, n=6) (Figure 1B). We
never observed motor or behavioral seizures neither in controls
nor in Lev-treated animals.
A second group of controls and of rats receiving 100mg/kg
Lev were sacrificed 72 hours after pMCAO to establish whether
the neuroprotection elicited by a single injection of Lev still
persisted at that time. Normalized volume of the ischemic
lesion (43.9 ± 1.1 vs 24.1 ± 1.9 % of the whole hemisphere in
Figure 1.  Levetiracetam reduces the ischemic brain damage evaluated 24 hours after pMCAO.  A, percent ischemic damage
in vehicle- and Lev-treated ischemic rats. The bar graph reports the mean+SEM of the volume of the ischemic lesion normalized to
the volume of the entire hemisphere ipsilateral to vessel occlusion. See the methods section for more details. The microphotographs
on the top of the bars show representative TTC-stained brain slices obtained 24 after pMCAO from rats belonging to the respective
experimental groups. Note that the ischemic area is smaller in the animal receiving the highest dose of Lev than in the other two
rats.
B, neurological deficits in vehicle and Lev-treated ischemic rats, evaluated 24 hours after pMCAO. The scatter graph shows the
individual data of the Clark’s score for generalized neurological deficits in rats receiving vehicle, 50mg/kg or 100 mg/kg Lev as
indicated. *, p<0.05 vs vehicle (n=6 in all groups).
doi: 10.1371/journal.pone.0080852.g001
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controls and 100mg/kg Lev treated rats, p<0.05, n=6 in both
groups) and Clark’s neurological scores (median of deficit
scores: 5.5 vs 3 in control and 100mg/kg Lev treated rats,
respectively) were still smaller in Lev treated rats than in
controls 72 hours after pMCAO (Figure 2A and B).
Effect of Levetiracetam on the non convulsive seizure
discharges occurring after pMCAO
To establish whether the neuroprotective dose of Lev
(100mg/kg) affected NCS generation or propagation we
performed EEG recordings in ischemic rats receiving this dose
of the drug or its vehicle. In addition, EEG activity was also
monitored in two different groups of sham-operated rats, the
first ip-injected with Lev and the second with its vehicle.
Baseline EEG activity was recorded in all the animals for 30
min before Lev or vehicle injection. In these awake and freely
moving animals, visual inspection of the EGG traces showed a
predominance of slow activity (Figure 3 and Figure 4A). Power
spectra analysis confirmed that the majority of brain electrical
activity was in the delta frequency range (Figure 4B).
Both in rats receiving Lev and in controls, baseline EEG
pattern was dramatically modified after brain ischemia.
Conversely, no change in EEG activity was observed in sham-
operated rats (data not shown). In rats subjected to pMCAO,
when EEG recording was started again, 20 min after vessel
occlusion, spontaneous cortical electrical activity was greatly
Figure 2.  Levetiracetam neuroprotection persists 72 hours after pMCAO.  A, percent ischemic damage in vehicle and Lev-
treated ischemic rats. The bar graph reports the mean+SEM of the volume of the ischemic lesion normalized to the volume of the
entire hemisphere ipsilateral to vessel occlusion. See the methods section for more details. The microphotographs on the top of the
bars show representative TTC-stained brain slices obtained 72 after pMCAO from rats belonging to the respective experimental
groups. Note that the ischemic area is smaller in the animal receiving Lev than in the control rat.
B, neurological deficits evaluated 72 hrs after pMCAO in vehicle and Lev-treated ischemic rats. The scatter graph shows the
individual data of the Clark’s score for generalized neurological deficits in rats receiving vehicle, or 100 mg/kg Lev as indicated. *,
p<0.05 vs vehicle (n=6 in all groups).
doi: 10.1371/journal.pone.0080852.g002
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reduced respect to baseline in the ischemic but not in the
contralateral brain hemisphere where it remained fairly stable
(Figure 3 and Figure 4A). Consequently, in both groups, the
total power of the spectrum of the EEG recorded ipsilaterally to
Figure 3.  Effect of brain ischemia and of Levetiracetam on EEG activity.  The figure reports EEG recording samples of about
40 sec in duration obtained in a representative control (on the left) and a Lev-treated rat (on the right) before and after pMCAO. For
each animal, traces obtained immediately before, and 20 min, 120 min, 24 and 45 hours after pMCAO are reported. The traces
shown in the panels on the top of the figure were recorded ipsilaterally to MCAO whereas those in the bottom panels are from the
contralateral side. Note that EEG activity was markedly suppressed after pMCAO in the ipsi- but not in the contralateral brain
hemisphere. Note also that a significant EEG activity reappeared, in the form of NCSs, 120 min after pMCAO in the control rat and
only 24 hours after vessel occlusion in the Lev-treated rat. In the traces from the contralateral hemisphere reported in the bottom
panels, IRDAs can be easily identified as brief bursts occurring in isolation. Note that these events are already large and well
defined in traces obtained 120 min after pMCAO in control but not in Lev-treated rats in which they become clearly evident only after
24 hours.
doi: 10.1371/journal.pone.0080852.g003
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MCAO decreased down to about 40% of basal values and a
general decrease in EEG power occurred in the spectral trend
graph (Figure 5). No significant difference was observed
between Lev-treated and control rats in the extent of this
ischemia-induced suppression of the EEG activity. No change
was observed in the percent representation of the different
EEG spectral components neither in control nor in Lev-treated
rats. In the early phases after pMCAO, thus, the EEG spectrum
still showed a large prevalence of delta activity. On the
contrary, significant differences emerged, thereafter, between
rats receiving 100 mg/kg Lev and controls. Indeed, in controls
but not in rats treated with 100 mg/kg Lev, a paroxysmal
electrical activity appeared in the ischemic brain hemisphere by
30-45 min after pMCAO. This resurgent electrical activity
differed from that observed before the induction of ischemia
and was dominated by epileptiform discharges whose pattern
progressively changed over the following 6-12 hours. The first
events that we observed were rhythmic spikes (Figure 4A).
Figure 4.  Time course and electrophysiological characteristics of the non-convulsive seizures in control rats and in rats
treated with Levetiracetam.  A, examples of the different types of EEG activity recorded at different times after pMCAO in a control
(top) and in a Lev-treated (bottom) rat. Note the different time course of NCSs in the control and in the Lev-treated rat. In the control
rat, spike-wave activity predominated 45 and 90 min after pMCAO, polyspike-waves after 12 hours and polyspikes after 24 hours. In
the Lev-treated rat, NCSs appeared only 12 hour after pMCAO in the form of polyspike complexes. B, Spectral graph analysis of the
EEG traces obtained at different times from pMCAO in a control rat (top) and in a rat injected with 100mg/kg Lev. The graphs show
the frequency distribution of the power of the EEG signal in the frequency range from 0.25 up to 32 Hz. The main band components
of the EEG signal, delta, theta, alpha, beta 1, beta 2, are shown in different colors as detailed in the insets. Each spectral graph was
obtained by the analysis of 10 sec of artifact-free recordings. Note that, both in the control and in the Lev-treated rat, the
appearance of NCSs corresponded to a strong increase of the power in the regions of high theta and low alpha bands.
doi: 10.1371/journal.pone.0080852.g004
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Mean amplitude, duration and frequency of these events were
191.3 ± 11.9 μV, 41.9±2.7 sec, and 2.5 ± 0.9 Hz, respectively.
Single spikes were gradually replaced by spike-wave and
polyspike complexes that represented the prevalent electrical
discharges 120 min after pMCAO (Figure 4A). Twenty four
hours after the induction of pMCAO, EEG activity was virtually
composed only by arrhythmic polyspikes (Figure 4A). At
spectral analysis, NCSs corresponded to the appearance of a
distinct power peak in the regions of high theta and low alpha
activity with its maxima around 8 Hz (Figure 4B). In the spectral
trend graph NCSs appeared as brief high power episodes
superimposed on baseline (Figure 5A). These discharges
lasted approximately 45 hours. Afterwards, the EEG pattern
returned to normal.
Lev (100mg/kg) had a dramatic effect on the EEG response
to pMCAO but it did not modify background EEG activity in
sham-operated rats (data not shown). Specifically, this drug
reduced NCS occurrence (Figure 3 and Figure 4A). While in
control rats a mean of 6.4 + 0.3 NCSs occurred during the first
two hours of recordings after pMCAO, only 0.5 + 0.2 events
were observed in Lev-treated animals (p<0.001). In this group
of rats, NCSs were also shorter (13.2+2.8, vs 41.9+2.7 sec,
p<0.01, n=7) and their mean amplitude was lower than in
controls (74,3+5,9 vs 191,3+11,9 μV, p<0.01) (Figure 5B).
Approximately 6 hours after Lev injection and pMCAO
induction, EEG activity begun to increase in Lev-treated
animals (Figure 4A). The first EEG events observed in Lev-
treated rats were sharp-waves. They were followed by single
spikes and, then, by spike and wave, polyspikes and
polyspikes and wave (Figure 4A). At power spectra analysis,
the main spectral component peaked at approximately 8 Hz,
encompassing both theta and alpha activity (Figure 4B).
Therefore, this epileptiform activity recapitulated the electrical
events occurring at earlier stages in control animals. These
Figure 5.  Levetiracetam prevents the occurrence of non convulsive seizures.  A, representative spectral trend graphs showing
the changes in total EEG power after pMCAO in a control (left) and in a Lev-treated (right) rat. Each bar represents the total power
(in μV2) calculated by integration of the power spectrum of the EEG recorded during about 120 min interval. The bars colored in red
denote the data obtained during the first 90 min of recordings after pMCAO. Note the dramatic drop in total EEG power after
pMCAO induction both in the presence and in the absence of Lev. The sudden and transient increases in EEG power correspond to
the NCS activity that appears in the control but not in the Lev-treated rat. B, Number, duration and amplitude of NCSs in Lev treated
and in control animals. The bar graphs show from the left to the right the mean+SEM of the number, duration in sec and amplitude
in μV of the NCS observed during the first 2 hours after pMCAO in control (n=7) and Lev-treated (100mg/kg; n=7) rats. * p<0.05.
doi: 10.1371/journal.pone.0080852.g005
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events had, however, a power significantly smaller than those
observed in controls at the same time (23738.0+1306.0 vs
7675.0+255.6 μV2, p<.0.01, n=7). In Lev-treated rats, as in
controls, epileptiform discharges disappeared approximately 45
hours after pMCAO.
Both in control and in Lev-treated ischemic rats, EEG activity
was modified not only ipsilaterally but also contralaterally to
pMCAO. Specifically, an intermittent rhythmic delta activity
(IRDA) appeared in control rats by 45 min from ischemia
induction (Figure 3). This activity consisted of bursts in the
delta range lasting less than 10 sec that occurred more often in
isolation. IRDAs were still observed 24 hours after MCAO
whereas they completely disappeared by 45 hours. IRDAs also
occurred in rats treated with 100 mg/kg Lev but, when
compared 120 min from pMCAO, to those recorded at the
same time in control animals, they had a smaller amplitude
(97.3±8.3 vs 116.5±7.4 μV, p<0.01, n=7), lasted less (1.3±0.2
vs 4.53±0.8 sec, p<0.01, n=7) and their frequency was lower
(0.3±0.1 vs 1.24±0.1 Hz, p<0.05, n=7). As in control also in
Lev-treated rats IRDAs disappeared by 45 hours from MCAO
(Figure 3).
Discussion
The main finding of the present study was that the
antiepileptic drug Lev prevented the appearance of NCSs in
the parieto-temporal cortex of rats subjected to pMCAO.
Parallel to this electrophysiological effect a significant reduction
in the ischemic brain damage caused by this surgical
procedure also occurred.
Since the seminal work of Leao [30] it has been established
that brain ischemia causes relevant changes in cortical
electrical activity both in men and in experimental animals (see
21 for review). In accordance, in our control group, we
observed prominent changes in EEG activity after experimental
ischemia. The alterations that we observed are similar to those
described by Lu and coworkers [31] who reported a very
detailed topographical and spectral analysis of the electrical
events originating in the cerebral cortex of rats subjected to
MCAO. In particular, in our experiments, a profound
suppression of cortical electrical activity appeared in rats
subjected to pMCAO as early as 15-20 min after the initial
insult in the ischemic but not in the contralateral brain
hemisphere. The evidence that no suppression of background
EEG activity did occur in sham-operated rats further supports
the idea that it was actually caused by brain ischemia and it
was not a mere consequence of surgery and/or anesthesia.
Ischemia-induced loss of EEG activity is currently considered
the consequence of a non-spreading depression of the
synaptic activity caused either by the impairment of vesicular
release of excitatory neurotransmitters [32] or by the massive
release of adenosine in the lesioned brain [33]. Approximately
45 min after the induction of ischemia, we observed a
resurgent but abnormal EEG activity in the form of NCSs on
the side of middle cerebral artery occlusion. Interestingly, the
electrophysiological characteristics of these events gradually
changed over time. Specifically, whereas during the first 90 min
the EEG activity essentially consisted of single high voltage
and low frequency spikes, spike-wave discharges became
prevalent after 360 min. Brain ischemia also induced the
appearance of an abnormal EEG activity in the brain
hemisphere contralateral to pMCAO. This activity consisted of
brief bursts in the delta frequency range and was similar to
IRDAs described by Hartings et al. in experimental brain
ischemia in the rat [25]. Its genesis is still controversial but it
could be an indirect consequence of the damage occurring in
far brain regions being caused, for instance, by subtle
dysfunction in midline cerebral structures due to the increase in
intracranial pressure [25].
A single intraperitoneal injection of Lev at the dose of 100
mg/kg virtually abolished both NCSs and IRDAs though this
effect was only transient. In animals receiving the drug at this
concentration EEG remained markedly suppressed till 24 hours
after pMCAO when an epileptiform activity appeared in Lev-
treated rats. This activity became, then, progressively more
intense though it was significantly lower than in controls. This
gradual reappearance of activity can be easily explained by
pharmacokinetics considerations. The half life of the drug in the
rat is, indeed, approximately 3 hours in blood and 5 hours in
cerebrospinal fluid [34].
The mechanism responsible for the suppression of
postischemic electrical activity by Lev in both the cortex ipsi
and contralateral to pMCAO remains to be determined.
However, it could be dependent on the ability of this drug to
suppress neurotransmitter release [12] either by interacting
with the vesicular protein SV2 [11] that controls the priming of
synaptic vesicles for fusion [35-37], or by decreasing Ca2+
release from the intracellular stores [38]. The integrity of
glutamatergic neurotransmission seems, indeed, to be
essential for the propagation of spreading depolarization waves
in experimental brain ischemia in the rat [39]. These events
that can be measured as NCSs at EEG are generated at the
border between the core and the penumbra of the ischemic
lesion when the anoxic depolarization invades the still alive
brain tissue of the latter region (see 21 for review). This
depolarization wave, presumably, activates local brain
networks along which NCSs are then propagated. In
accordance with this theory, NCSs are significantly increased
in transgenic mice overexpressing mutated, hyperfunctional
forms of the P/Q type channels, the predominant form of
voltage-gated Ca2+ channels responsible for neurotransmitter
release in the glutamatergic terminals [40]. Conversely, they
can be blocked by inducing a general inhibition of
neurotransmission with the simultaneous application of
blockers of AMPA/kainate and NMDA receptors and of voltage
gated Na+ and Ca2+ channels [41]. The need of a marked
suppression of neurotransmitter release for a significant NCS
suppression could explain why not all the antiepileptic drugs
are effective against these events [22] that are considered
especially sensitive only to compounds acting on multiple
targets [42].
In our experiments, the brain damage induced by ischemia
was significantly smaller in the animals that received Lev than
in controls. These data resemble those reported by Hanon and
Klitgaard [8] in rats subjected to the transient occlusion of the
middle cerebral artery. Surprisingly, in brain slices undergoing
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oxygen and glucose deprivation in vitro, Lev did not reduce the
ischemic damage evaluated either as propidium iodide staining
[20] or as suppression of field electrical responses to
extracellular stimulation [43]. Moreover, this drug did not
suppress the spreading depression elicited by oxygen and
glucose deprivation in rat cortical brain slices in vitro [44]. The
inconsistency between the data obtained in vitro and in living
animals suggests that Lev needs intact brain networks to exert
its favourable effects in ischemia. This fits well with the idea
that this drug could suppress the synaptic propagation of NCS.
Electrocorticographic and fMRI data show, indeed, that both in
humans and in rodents these depolarizing waves cycle around
the ischemic core for several days after the ischemic insult [23].
We also have to remind that, recently, Meehan and co-workers
[12,45] showed that Lev has to enter the synapse through the
recycling vesicular route to exert its antiepileptic activity. This
implies that a certain degree of synaptic activity could be
needed to see Lev-induced neuroprotection. Therefore, we can
speculate that the lack of neuroprotection in the preparations in
vitro is the result of their low or absent spontaneous network
activity. A significant neuroprotection in vivo despite the lack of
a neuroprotective effect in vitro has been reported also for
gabapentin and ethosuximide [46]. Intriguingly, also these
compounds significantly suppressed NCS occurrence [46].
In conclusion, we showed that Lev suppresses NCSs in an
animal model of stroke. Because NCSs contribute to enlarge
the ischemic lesion [23] our findings could help explaining the
neuroprotective activity of this drug. Considering that NCSs
also have a role in post-stroke epileptogenesis [24], the ability
of Lev to suppress these electrical events adds new arguments
to suggest that this drug could be useful for the prophylaxis of
late post-stroke seizures. This form of epilepsy represents a
major problem in clinical neurology as it occurs in 11.5% of the
patients surviving stroke [47] and accounts for the more
prevalent form of acquired epilepsy in adults [48,49]. While
other antiepileptic drugs like ethosuximide, gabapentin,
topiramate, phosphenytoin, and valproate also suppress NCSs
after MCAO [22,50], the better safety profile of Lev respect to
these older drugs warrants further studies to validate its early
use in stroke patients.
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